Published in Cancer Res on March 01, 1972
Cultures of Chlamydia trachomatis in mouse peritoneal macrophages: factors affecting organism growth. Infect Immun (1978) 1.25
Effect of phenobarbital on plasma levels of cyclophosphamide and its metabolites in the mouse. Br J Cancer (1978) 0.95
Effect of cyclophosphamide in vitro and on vaccinia virus replication in tissue culture. J Virol (1977) 0.82
Treatment of vasculitis. Br J Clin Pharmacol (1993) 0.80
Cimetidine enhancement of cyclophosphamide antitumour activity. Br J Cancer (1982) 0.80
Increase in the gastrointestinal absorption and in tissue storage of cyclophosphamide in L-1210 leukaemic mice at an advanced stage of the disease. Br J Cancer (1975) 0.77
Effects of the induction of hepatic microsomal metabolism on the toxicity of cyclophosphamide. Br J Cancer (1985) 0.75
High apoptosis-inducing and antitumor activities of the products of biological but not chemical cyclophosphamide activation. Dokl Biol Sci (2002) 0.75
Asymmetrical retinoic acid synthesis in the dorsoventral axis of the retina. Development (1992) 1.50
Induction of drug metabolism. I. Differences in the mechanisms by which polycyclic hydrocarbons and phenobarbital produce their inductive effects on microsomal N-demethylating systems. Mol Pharmacol (1969) 1.28
Evidence for a new P-450 hemoprotein in hepatic microsomes from methylcholanthrene treated rats. Biochem Biophys Res Commun (1966) 1.26
Bioassay and relative cytotoxic potency of cyclophosphamide metabolites generated in vitro and in vivo. Cancer Res (1973) 1.14
Class 1 and class 3 aldehyde dehydrogenase levels in the human tumor cell lines currently used by the National Cancer Institute to screen for potentially useful antitumor agents. Adv Exp Med Biol (1997) 1.13
Induction of drug metabolism. II. Qualitative differences in the microsomal N-demethylating systems stimulated by polycyclic hydrocarbons and by phenobarbital. Mol Pharmacol (1969) 1.09
Cellular levels of class 1 and class 3 aldehyde dehydrogenases and certain other drug-metabolizing enzymes in human breast malignancies. Clin Cancer Res (1997) 1.00
Identification of human liver aldehyde dehydrogenases that catalyze the oxidation of aldophosphamide and retinaldehyde. Biochem Pharmacol (1992) 1.00
Identification of a class 3 aldehyde dehydrogenase in human saliva and increased levels of this enzyme, glutathione S-transferases, and DT-diaphorase in the saliva of subjects who continually ingest large quantities of coffee or broccoli. Clin Cancer Res (1995) 0.94
Metabolism of cyclophosphamide by rat hepatic microsomes. Cancer Res (1971) 0.93
Plasma concentrations of 4-hydroxycyclophosphamide and phosphoramide mustard in patients repeatedly given high doses of cyclophosphamide in preparation for bone marrow transplantation. Cancer Treat Rep (1984) 0.91
Identification of mouse liver aldehyde dehydrogenases that catalyze the oxidation of retinaldehyde to retinoic acid. Biochem Pharmacol (1991) 0.90
Identification and characterization of a novel class 3 aldehyde dehydrogenase overexpressed in a human breast adenocarcinoma cell line exhibiting oxazaphosphorine-specific acquired resistance. Biochem Pharmacol (1993) 0.89
Conversion of 4-hydroperoxycyclophosphamide and 4-hydroxycyclophosphamide to phosphoramide mustard and acrolein mediated by bifunctional catalysis. Cancer Res (1982) 0.88
NADPH-dependent enzyme-catalyzed reduction of aldophosphamide, the pivotal metabolite of cyclophosphamide. Biochem Pharmacol (1993) 0.87
Intrinsic cellular resistance to oxazaphosphorines exhibited by a human colon carcinoma cell line expressing relatively large amounts of a class-3 aldehyde dehydrogenase. Biochem Pharmacol (1994) 0.87
Interleukin-1 and tumor necrosis factor alpha induce class 1 aldehyde dehydrogenase mRNA and protein in bone marrow cells. Leuk Lymphoma (1995) 0.87
Identification of the mouse aldehyde dehydrogenases important in aldophosphamide detoxification. Cancer Res (1990) 0.86
Effect of aldehyde dehydrogenase inhibitors on the ex vivo sensitivity of human multipotent and committed hematopoietic progenitor cells and malignant blood cells to oxazaphosphorines. Cancer Res (1987) 0.86
Inhibition of human class 3 aldehyde dehydrogenase, and sensitization of tumor cells that express significant amounts of this enzyme to oxazaphosphorines, by the naturally occurring compound gossypol. Adv Exp Med Biol (1997) 0.86
PLasma half-life and urinary excretion of cyclophosphamide in children. Cancer Treat Rep (1981) 0.85
Cytotoxic activity relative to 4-hydroxycyclophosphamide and phosphoramide mustard concentrations in the plasma of cyclophosphamide-treated rats. Cancer Res (1983) 0.84
Influence of pH on the cytotoxic activity of chlorambucil. Biochem Pharmacol (1983) 0.83
Differential effects of Walker 256 carcinosarcoma cells growing subcutaneously, intramuscularly, or intraperitoneally on hepatic microsomal mixed-function oxygenase activity. Drug Metab Dispos (1978) 0.83
Relative contribution of human erythrocyte aldehyde dehydrogenase to the systemic detoxification of the oxazaphosphorines. Drug Metab Dispos (1997) 0.82
Kinetics of cyclophosphamide biotransformation in vivo. Cancer Res (1980) 0.82
Half-life of oxazaphosphorines in biological fluids. Drug Metab Dispos (1985) 0.81
Inhibition of human class 3 aldehyde dehydrogenase, and sensitization of tumor cells that express significant amounts of this enzyme to oxazaphosphorines, by chlorpropamide analogues. Biochem Pharmacol (1998) 0.81
Evidence for an aldehyde possessing alkylating activity as the primary metabolite of cyclophosphamide. Cancer Res (1973) 0.80
Aldehyde dehydrogenase activity as the basis for the relative insensitivity of murine pluripotent hematopoietic stem cells to oxazaphosphorines. Biochem Pharmacol (1985) 0.80
Sex-dependent differences in drug metabolism in the rat. IV. Effect of morphine administration. Drug Metab Dispos (1974) 0.79
Human breast adenocarcinoma MCF-7/0 cells electroporated with cytosolic class 3 aldehyde dehydrogenases obtained from tumor cells and a normal tissue exhibit differential sensitivity to mafosfamide. Drug Metab Dispos (1995) 0.79
Therapeutic efficacy of cyclophosphamide as a function of inhibition of its metabolism. Cancer Res (1972) 0.79
Inhibition of diacylglycerol:CDPcholine cholinephosphotransferase activity by dimethylaminoethyl p-chlorophenoxyacetate. Lipids (1978) 0.78
Multienzyme-mediated stable and transient multidrug resistance and collateral sensitivity induced by xenobiotics. Cancer Chemother Pharmacol (1997) 0.78
Cytotoxic activity of alkylating agents in the presence of centrophenoxine and its hydrolysis products. J Pharmacol Exp Ther (1977) 0.78
Phenolic antioxidant-induced overexpression of class-3 aldehyde dehydrogenase and oxazaphosphorine-specific resistance. Biochem Pharmacol (1995) 0.78
Yeast aldehyde dehydrogenase sensitivity to inhibition by chlorpropamide analogues as an indicator of human aldehyde dehydrogenase sensitivity to these agents. Adv Exp Med Biol (1997) 0.77
Aldehyde dehydrogenase-catalyzed bioinactivation of cyclophosphamide. Prog Clin Biol Res (1989) 0.77
Sensitivity of murine B- and T-lymphocytes to oxazaphosphorine and non-oxazaphosphorine nitrogen mustards. Biochem Pharmacol (1985) 0.77
Restoration of sensitivity to oxazaphosphorines by inhibitors of aldehyde dehydrogenase activity in cultured oxazaphosphorine-resistant L1210 and cross-linking agent-resistant P388 cell lines. Cancer Res (1985) 0.77
Metabolism of 4-hydroxycyclophosphamide/aldophosphamide in vitro. Biochem Pharmacol (1980) 0.77
Identification of the class-3 aldehyde dehydrogenases present in human MCF-7/0 breast adenocarcinoma cells and normal human breast tissue. Biochem Pharmacol (1994) 0.77
Collateral sensitivity to cross-linking agents exhibited by cultured L1210 cells resistant to oxazaphosphorines. Cancer Res (1985) 0.76
Sensitivity of aldehyde dehydrogenases in murine tumor and hematopoietic progenitor cells to inhibition by chloral hydrate as determined by the ability of chloral hydrate to potentiate the cytotoxic action of mafosfamide. Biochem Pharmacol (1993) 0.76
Identification of a methylcholanthrene-induced aldehyde dehydrogenase in a human breast adenocarcinoma cell line exhibiting oxazaphosphorine-specific acquired resistance. Cancer Res (1994) 0.76
Kinetic characterization of the catalysis of "activated" cyclophosphamide (4-hydroxycyclophosphamide/aldophosphamide) oxidation to carboxyphosphamide by mouse hepatic aldehyde dehydrogenases. Biochem Pharmacol (1988) 0.75
Potentiation of the cytotoxic action of mafosfamide by N-isopropyl-p-formylbenzamide, a metabolite of procarbazine. Cancer Res (1991) 0.75
Interaction between duck hepatitis virus and DDT in ducks. Res Commun Chem Pathol Pharmacol (1971) 0.75
Over-expression of glutathione S-transferases, DT-diaphorase and an apparently tumour-specific cytosolic class-3 aldehyde dehydrogenase by Warthin tumours and mucoepidermoid carcinomas of the human parotid gland. Arch Oral Biol (1996) 0.75
Cytotoxic activity of mechlorethamine and melphalan against cultured tumor cells: potentiation by caffeine. J Pharmacol Exp Ther (1978) 0.75
Further studies on the conversion of 4-hydroxyoxazaphosphorines to reactive mustards and acrolein in inorganic buffers. Cancer Res (1983) 0.75
Substrate specificity and other characteristics of a novel aldehyde dehydrogenase present in female DBA/2 mouse liver. Drug Metab Dispos (1992) 0.75
Ex vivo treatment of murine splenocyte-supplemented bone marrow inocula with mafosfamide prior to allogeneic transplantation in an attempt to prevent lethal graft-versus-host disease without compromising engraftment. Immunopharmacol Immunotoxicol (1988) 0.75
Effect of the aldehyde dehydrogenase inhibitor, cyanamide, on the ex vivo sensitivity of murine multipotent and committed hematopoietic progenitor cells to mafosfamide (ASTA Z 7557). Immunopharmacol Immunotoxicol (1987) 0.75
Effects of aldehyde dehydrogenase inhibitors on the ex vivo sensitivity of murine late spleen colony-forming cells (day-12 CFU-S) and hematopoietic repopulating cells to mafosfamide (ASTA Z 7557). Biochem Pharmacol (1987) 0.75
Overexpression or polycyclic aromatic hydrocarbon-mediated induction of an apparently novel class 3 aldehyde dehydrogenase in human breast adenocarcinoma cells and its relationship to oxazaphosphorine-specific acquired resistance. Adv Exp Med Biol (1993) 0.75
Microdetermination of caffeine in blood by gas chromatography--mass spectrometry. J Chromatogr (1978) 0.75
Potentiation of antitumor drug action by centrophenoxine: specificity. J Pharmacol Exp Ther (1977) 0.75
Inhibition by cyanamide of 4-hydroxycyclophosphamide/aldophosphamide oxidation to carboxyphosphamide. Biochem Pharmacol (1981) 0.75
Influence of diuretics on urinary general base catalytic activity and cyclophosphamide-induced bladder toxicity. Cancer Treat Rep (1982) 0.75
Potentiation of the cytotoxic action of melphalan and "activated" cyclophosphamide against cultured tumor cells by centrophenoxine. J Pharmacol Exp Ther (1977) 0.75
Sensitivity of primary clonogenic blasts from acute lymphoblastic leukemia patients to an activated cyclophosphamide, viz., mafosfamide. Leuk Lymphoma (1994) 0.75
Studies on the mechanism of template stability: cytoplasmic DNA-like RNA in hepatocellular carcinomas. Cancer Res (1970) 0.75